signeR: an empirical Bayesian approach to mutational signature discovery.
about
Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxelAristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia.Computational approaches for discovery of mutational signatures in cancer.MutationalPatterns: comprehensive genome-wide analysis of mutational processes.
P2860
signeR: an empirical Bayesian approach to mutational signature discovery.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
signeR: an empirical Bayesian approach to mutational signature discovery.
@en
signeR: an empirical Bayesian approach to mutational signature discovery.
@nl
type
label
signeR: an empirical Bayesian approach to mutational signature discovery.
@en
signeR: an empirical Bayesian approach to mutational signature discovery.
@nl
prefLabel
signeR: an empirical Bayesian approach to mutational signature discovery.
@en
signeR: an empirical Bayesian approach to mutational signature discovery.
@nl
P2093
P2860
P356
P1433
P1476
signeR: an empirical Bayesian approach to mutational signature discovery.
@en
P2093
Emmanuel Dias-Neto
Israel T da Silva
Rafael A Rosales
Renan Valieris
Rodrigo D Drummond
P2860
P356
10.1093/BIOINFORMATICS/BTW572
P407
P577
2016-09-01T00:00:00Z